Four-year data support Endologix' Powerlink AAA (abdominal aortic aneurysm) stent graft system:
This article was originally published in Clinica
Executive Summary
Endologix says that four-year data are now available to support the durability of its Powerlink stent graft system for treating abdominal aortic aneurysms (AAAs). Follow-up results from the pivotal trial found that only 24 of the 192 patients treated with the minimally-invasive device required secondary procedures, the majority of which were for type II endoleak, indicating that the need for a secondary procedure was not device-specific, the Irvine, California firm said. In addition, 97.9% of the 53 patients followed for 48 months were free from AAA-related mortality and there were no reports of graft material failure. Powerlink was approved for sale in the US in October 2004.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.